Incannex Healthcare (IXHL) EBIT (2022 - 2026)

Incannex Healthcare (IXHL) has reported EBIT for 5 consecutive years, with -$4.0 million the latest figure, recorded in Q1 2026.

• Quarterly EBIT rose 19.09% year-over-year to -$4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.4 million (up 2.46% YoY) and the FY2025 annual result came in at -$23.8 million, up 20.81% from the prior year.
• EBIT climbed to -$4.0 million in Q1 2026 per IXHL's latest filing, from -$7.0 million in the prior quarter.
• Over the last five years, EBIT for IXHL reached as high as -$3.6 million in Q4 2022 and fell as low as -$9.7 million in Q2 2024.
• A 5-year average of -$5.9 million and a median of -$5.6 million in 2024 frame the typical range for EBIT.
• The largest YoY upside for EBIT was 37.32% in 2024 against a maximum downside of 132.33% in 2024.
• Year by year, EBIT stood at -$3.6 million in 2022, then plunged by 119.37% to -$8.0 million in 2023, then jumped by 37.32% to -$5.0 million in 2024, then slumped by 39.79% to -$7.0 million in 2025, then jumped by 42.13% to -$4.0 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$4.0 million, -$7.0 million, and -$6.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.